1. Acute Retinal Necrosis: Experience in a Reference Center in Santander - Colombia.
- Author
-
Rangel CM, Restrepo-Arango M, Mejía-Salgado G, Gómez-Rocha MA, Gómez Velasco M, García MF, and Moreno JJ
- Subjects
- Humans, Male, Female, Colombia, Middle Aged, Adult, Polymerase Chain Reaction, Ganciclovir therapeutic use, Ganciclovir analogs & derivatives, DNA, Viral analysis, DNA, Viral genetics, Administration, Oral, Valganciclovir therapeutic use, Retrospective Studies, Intravitreal Injections, Tomography, Optical Coherence, Fluorescein Angiography, Young Adult, Aged, Retinal Necrosis Syndrome, Acute diagnosis, Retinal Necrosis Syndrome, Acute virology, Retinal Necrosis Syndrome, Acute drug therapy, Antiviral Agents therapeutic use, Valacyclovir therapeutic use, Visual Acuity physiology, Acyclovir therapeutic use, Acyclovir analogs & derivatives, Eye Infections, Viral diagnosis, Eye Infections, Viral virology, Eye Infections, Viral drug therapy
- Abstract
Introduction: Acute retinal necrosis (ARN) is a severe eye disease demanding swift treatment to prevent blindness. Early action involving antiviral medications and corticosteroids is crucial for optimal visual outcomes., Objective: We present an ARN case series showcasing treatment experience and results., Methodology: Patients diagnosed with ARN based on SUN Working Group 2021 criteria were included; all underwent comprehensive eye exams, PCR analysis, and imaging., Results: Eight patients were studied; PCR confirmed ARN in six. Induction treatment, either oral valacyclovir (5/8) or intravenous acyclovir (3/8), lasted 10-14 days. Maintenance included oral valacyclovir (6/8), oral valganciclovir (2/8) for six months, along with intravitreal ganciclovir. Visual outcomes were similar for oral and intravenous therapies; poor baseline acuity and macular involvement tend to result in a worse final acuity., Conclusions: Swift treatment is vital to ARN management. Our findings emphasize effective treatment strategies' role in visual prognosis., Abbreviations: ACV: Acyclovir; BCVA: Best Corrected Visual Acuity; CMV: Cytomegalovirus; EBV: Epstein Barr Virus; FTA-ABS: Fluorescent treponemal antibody absorption test; HSV 1-2: Herpes simplex virus 1-2; HIV: Human Immunodeficiency Virus; IV-ACV: Intravenous- Acyclovir; PCR: Polymerase Chain Reaction;Tg: Toxoplasma gondii ; VZV: Varicella Zoster Virus; VCV: Valacyclovir; VDRL: Venereal disease research laboratory test.
- Published
- 2024
- Full Text
- View/download PDF